The Clinical Efficacy of Immunomodulators in RA Patients
ConditionArthritis, Rheumatoid
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-80
SponsorQilu Hospital of Shandong University
About this trial
This study includes naive patients and csDMARDs-IR RA patients, treated with different regimens such as Iguratimod combination of different csDMARDs, or csDMARD with TNF inhibitors for 24 weeks. The disease activity and drug response will be observed. The immune disorder and synovial function will be evaluated at the same time.
Eligibility criteria
Qualifiers
ACR 1987 rheumatoid arthritis classification criteria
morning stiffness lasting at least 1 hour (≥6w)
there are 3 or more joint areas swollen (≥6w)
swelling of the wrist, metacarpophalangeal, and proximal phalangeal joint areas (≥6w)
Disqualifiers
Patients with combined active hepatitis
Patients with active tuberculosis
Patients withinfection and malignancy
Trial design
Treatments tested in this trial
- Iguratimod
- Methotrexate
- Adalimumab Injection
- Leflunomide
- Hydroxychloroquine
Treatment groups
400 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov